Array Technologies (ARRY)
(Delayed Data from NSDQ)
$11.12 USD
+0.17 (1.55%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $11.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Brokerage Reports
0 items in cart
[ARRY]
Reports for Purchase
Showing records 541 - 560 ( 563 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
We are placing Array BioPharma Under Review due to the departure from the firm of analyst, Simos Simeonidis
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
We are placing Array BioPharma Under Review due to the departure from the firm of analyst, Simos Simeonidis
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
Reports 2Q11 numbers; waiting for selumetinib (MEK inhibitor) data this year
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
Reports 2Q11 numbers; waiting for selumetinib (MEK inhibitor) data this year
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
KSP inhibitor looks good in heavily pretreated Multiple Myeloma patients
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
Reports 1Q11; keeping spending in check, while advancing internal pipeline
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Industry: Medical - Biomedical and Genetics
13 clinical compounds at a $157M market cap: should interest investors with long-term horizon
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.